Literature DB >> 19559060

Methamphetamine treatment causes delayed decrease in novelty-induced locomotor activity in mice.

Irina N Krasnova1, Amber B Hodges, Bruce Ladenheim, Raina Rhoades, Crystal G Phillip, Angela Cesena, Ekaterina Ivanova, Christine F Hohmann, Jean Lud Cadet.   

Abstract

Methamphetamine (METH) is a psychostimulant that causes damage to dopamine (DA) axons and to non-monoaminergic neurons in the brain. The aim of the present study was to investigate short- and long-term effects of neurotoxic METH treatment on novelty-induced locomotor activity in mice. Male BALB/c mice, 12-14 weeks old, were injected with saline or METH (i.p., 7.5 mg/kg x 4 times, every 2 h). Behavior and neurotoxic effects were assessed at 10 days, 3 and 5 months following drug treatment. METH administration caused marked decreases in DA levels in the mouse striatum and cortex at 10 days post-drug. However, METH did not induce any changes in novelty-induced locomotor activity. At 3 and 5 months after treatment METH-exposed mice showed significant recovery of DA levels in the striatum and cortex. In contrast, these animals demonstrated significant decreases in locomotor activity at 5 months in comparison to aged-matched control mice. Further assessment of METH toxicity using TUNEL staining showed that the drug induced increased cell death in the striatum and cortex at 3 days after administration. Taken together, these data suggest that delayed deficits in novelty-induced locomotor activity observed in METH-exposed animals are not due to neurodegeneration of DA terminals but to combined effects of METH and age-dependent dysfunction of non-DA intrinsic striatal and/or corticostriatal neurons.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19559060      PMCID: PMC2731825          DOI: 10.1016/j.neures.2009.06.007

Source DB:  PubMed          Journal:  Neurosci Res        ISSN: 0168-0102            Impact factor:   3.304


  62 in total

Review 1.  Aging and caloric restriction in nonhuman primates: behavioral and in vivo brain imaging studies.

Authors:  D K Ingram; S Chefer; J Matochik; T D Moscrip; J Weed; G S Roth; E D London; M A Lane
Journal:  Ann N Y Acad Sci       Date:  2001-04       Impact factor: 5.691

Review 2.  Ageing and the nigrostriatal dopaminergic system.

Authors:  S Reeves; C Bench; R Howard
Journal:  Int J Geriatr Psychiatry       Date:  2002-04       Impact factor: 3.485

3.  A twin study of the neuropsychological consequences of stimulant abuse.

Authors:  Rosemary Toomey; Michael J Lyons; Seth A Eisen; Hong Xian; Sunanta Chantarujikapong; Larry J Seidman; Stephen V Faraone; Ming T Tsuang
Journal:  Arch Gen Psychiatry       Date:  2003-03

4.  Methamphetamine-induced neurotoxicity is attenuated in transgenic mice with a null mutation for interleukin-6.

Authors:  B Ladenheim; I N Krasnova; X Deng; J M Oyler; A Polettini; T H Moran; M A Huestis; J L Cadet
Journal:  Mol Pharmacol       Date:  2000-12       Impact factor: 4.436

5.  Intracerebroventricular administration of substance P increases dopamine content in the brain of 6-hydroxydopamine-lesioned rats.

Authors:  I N Krasnova; E R Bychkov; V I Lioudyno; O E Zubareva; S A Dambinova
Journal:  Neuroscience       Date:  2000       Impact factor: 3.590

6.  Long-term changes in basal ganglia function after a neurotoxic regimen of methamphetamine.

Authors:  D E Chapman; G R Hanson; R P Kesner; K A Keefe
Journal:  J Pharmacol Exp Ther       Date:  2001-02       Impact factor: 4.030

7.  Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers.

Authors:  N D Volkow; L Chang; G J Wang; J S Fowler; M Leonido-Yee; D Franceschi; M J Sedler; S J Gatley; R Hitzemann; Y S Ding; J Logan; C Wong; E N Miller
Journal:  Am J Psychiatry       Date:  2001-03       Impact factor: 18.112

8.  Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET.

Authors:  Y Sekine; M Iyo; Y Ouchi; T Matsunaga; H Tsukada; H Okada; E Yoshikawa; M Futatsubashi; N Takei; N Mori
Journal:  Am J Psychiatry       Date:  2001-08       Impact factor: 18.112

9.  Methamphetamine causes widespread apoptosis in the mouse brain: evidence from using an improved TUNEL histochemical method.

Authors:  X Deng; Y Wang; J Chou; J L Cadet
Journal:  Brain Res Mol Brain Res       Date:  2001-09-10

10.  Mice with partial deficiency of c-Jun show attenuation of methamphetamine-induced neuronal apoptosis.

Authors:  Xiaolin Deng; Subramaniam Jayanthi; Bruce Ladenheim; Irina N Krasnova; Jean Lud Cadet
Journal:  Mol Pharmacol       Date:  2002-11       Impact factor: 4.436

View more
  11 in total

1.  Effects of exposure to amphetamine derivatives on passive avoidance performance and the central levels of monoamines and their metabolites in mice: correlations between behavior and neurochemistry.

Authors:  Kevin Sean Murnane; Shane Alan Perrine; Brendan James Finton; Matthew Peter Galloway; Leonard Lee Howell; William Edward Fantegrossi
Journal:  Psychopharmacology (Berl)       Date:  2011-10-13       Impact factor: 4.530

Review 2.  Methamphetamine addiction: involvement of CREB and neuroinflammatory signaling pathways.

Authors:  Irina N Krasnova; Zuzana Justinova; Jean Lud Cadet
Journal:  Psychopharmacology (Berl)       Date:  2016-02-12       Impact factor: 4.530

3.  Mutant DISC1 affects methamphetamine-induced sensitization and conditioned place preference: a comorbidity model.

Authors:  Vladimir M Pogorelov; Jun Nomura; Jongho Kim; Geetha Kannan; Yavuz Ayhan; Chunxia Yang; Yu Taniguchi; Bagrat Abazyan; Heather Valentine; Irina N Krasnova; Atsushi Kamiya; Jean Lud Cadet; Dean F Wong; Mikhail V Pletnikov
Journal:  Neuropharmacology       Date:  2011-02-17       Impact factor: 5.250

4.  Methamphetamine-induced locomotor changes are dependent on age, dose and genotype.

Authors:  Renee L Good; Richard A Radcliffe
Journal:  Pharmacol Biochem Behav       Date:  2010-12-14       Impact factor: 3.533

5.  Mouse strain- and age-dependent effects of binge methamphetamine on dopaminergic signaling.

Authors:  Renee L Good; Li-Ping Liang; Manisha Patel; Richard A Radcliffe
Journal:  Neurotoxicology       Date:  2011-07-20       Impact factor: 4.294

6.  Dysregulation of iron homeostasis and methamphetamine reward behaviors in Clk1-deficient mice.

Authors:  Peng-Ju Yan; Zhao-Xiang Ren; Zhi-Feng Shi; Chun-Lei Wan; Chao-Jun Han; Liu-Shuai Zhu; Ning-Ning Li; John L Waddington; Xue-Chu Zhen
Journal:  Acta Pharmacol Sin       Date:  2021-11-22       Impact factor: 7.169

7.  Methamphetamine induces low levels of neurogenesis in striatal neuron subpopulations and differential motor performance.

Authors:  I K Tulloch; L Afanador; L Baker; D Ordonez; H Payne; I Mexhitaj; E Olivares; A Chowdhury; J A Angulo
Journal:  Neurotox Res       Date:  2014-02-19       Impact factor: 3.911

8.  GluA3-deficiency in mice is associated with increased social and aggressive behavior and elevated dopamine in striatum.

Authors:  Abby Adamczyk; Rebeca Mejias; Kogo Takamiya; Jennifer Yocum; Irina N Krasnova; Juan Calderon; Jean Lud Cadet; Richard L Huganir; Mikhail V Pletnikov; Tao Wang
Journal:  Behav Brain Res       Date:  2012-01-21       Impact factor: 3.332

9.  Chronic methamphetamine administration causes differential regulation of transcription factors in the rat midbrain.

Authors:  Irina N Krasnova; Bruce Ladenheim; Amber B Hodges; Nora D Volkow; Jean Lud Cadet
Journal:  PLoS One       Date:  2011-04-25       Impact factor: 3.240

10.  Methamphetamine self-administration is associated with persistent biochemical alterations in striatal and cortical dopaminergic terminals in the rat.

Authors:  Irina N Krasnova; Zuzana Justinova; Bruce Ladenheim; Subramaniam Jayanthi; Michael T McCoy; Chanel Barnes; John E Warner; Steven R Goldberg; Jean Lud Cadet
Journal:  PLoS One       Date:  2010-01-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.